Your neighborhood may raise your risk of chronic kidney disease
(Drexel University) A neighborhood's overall socioeconomic status, including income and education-level, may influence its residents' risk of chronic kidney disease, according to a study recently published in SSM Population Health by researchers from Drexel University's Dornsife School of Public Health. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 23, 2020 Category: International Medicine & Public Health Source Type: news

Diet posttranslationally modifies the mouse gut microbial proteome to modulate renal function
Associations between chronic kidney disease (CKD) and the gut microbiota have been postulated, yet questions remain about the underlying mechanisms. In humans, dietary protein increases gut bacterial production of hydrogen sulfide (H2S), indole, and indoxyl sulfate. The latter are uremic toxins, and H2S has diverse physiological functions, some of which are mediated by posttranslational modification. In a mouse model of CKD, we found that a high sulfur amino acid–containing diet resulted in posttranslationally modified microbial tryptophanase activity. This reduced uremic toxin–producing activity and ameliorate...
Source: ScienceNOW - September 17, 2020 Category: Science Authors: Lobel, L., Cao, Y. G., Fenn, K., Glickman, J. N., Garrett, W. S. Tags: Medicine, Diseases, Microbiology reports Source Type: news

Good Lifestyle Choices Prevent Kidney as Well as CV Disease Good Lifestyle Choices Prevent Kidney as Well as CV Disease
Many of the same lifestyle choices recommended for cardiovascular disease prevention now shown to also prevent chronic kidney disease.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - September 16, 2020 Category: Primary Care Tags: Nephrology News Source Type: news

COVID-19 Takes Heavy Toll on Kidneys
The study authors warned that doctors should prepare for a significant rise in chronic kidney disease cases due to the pandemic. (Source: WebMD Health)
Source: WebMD Health - September 14, 2020 Category: Consumer Health News Source Type: news

COVID-19 Takes Heavy Toll on Kidneys
FRIDAY, Sept. 11, 2020 -- COVID-19 can damage the kidneys and increase patients'risk of needing kidney dialysis, researchers report. The study authors also warned that doctors should prepare for a significant rise in chronic kidney disease cases... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 14, 2020 Category: General Medicine Source Type: news

Chronic Kidney Disease COVID-19 coronavirus safety
What if You Have Chronic Kidney Disease During COVID-19? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - September 8, 2020 Category: General Medicine Source Type: news

Chronic Kidney Disease: How A Deeper Understanding of The Disease Is...
In this free webinar, attendees will learn about Chronic Kidney Disease (CKD) and its related comorbid conditions and the impact on clinical development. The webinar will explore tests related to the...(PRWeb September 02, 2020)Read the full story at https://www.prweb.com/releases/chronic_kidney_disease_how_a_deeper_understanding_of_the_disease_is_impacting_clinical_development_upcoming_webinar_hosted_by_xtalks/prweb17367048.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 2, 2020 Category: Pharmaceuticals Source Type: news

SGLT2 inhibitors can slow progression of chronic kidney disease
(ERA-EDTA) The CREDENCE trial [3] provided evidence that the SGLT2 inhibitor Canagliflozin slows the progression of CKD in individuals with type 2 diabetes (T2D) and CKD with albuminuria. The Phase III DAPA-CKD trial [1] has now shown that the SGLT2 inhibitor Dapagliflozin can significantly slow CKD progression in all CKD patients, not only in those with diabetes. This breakthrough in kidney disease treatment goes back to an incidental study finding of Professor Christoph Wanner, President of the ERA-EDTA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 31, 2020 Category: International Medicine & Public Health Source Type: news

FDA Requests More Data on Drug for Chronic Kidney Disease FDA Requests More Data on Drug for Chronic Kidney Disease
The agency sent a letter to manufacturer Tricida requesting more information on veverimer, a drug in development to treat metabolic acidosis associated with chronic kidney disease.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 27, 2020 Category: Intensive Care Tags: Nephrology News Source Type: news

Guideline Updated for Nutrition in Chronic Kidney Disease
THURSDAY, Aug. 27, 2020 -- The National Kidney Foundation and the Academy of Nutrition and Dietetics have updated the clinical practice guideline for nutrition in chronic kidney disease (CKD); the 2020 update was published as a supplement to the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 27, 2020 Category: Pharmaceuticals Source Type: news

Akebia Therapeutics Announces First Commercial Launch of VAFSEO(TM) (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic Kidney Disease, in Japan
VAFSEO Launch Marks Availability of Convenient Once-Daily Oral Treatment for Adult Patients on Dialysis and Not on Dialysis in Japan CAMBRIDGE, Mass., Aug. 26, 2020 -- (Healthcare Sales & Marketing Network) -- Akebia Therapeutics®, Inc. (Nasdaq: AK... Biopharmaceuticals, Product Launch Akebia Therapeutics, vadadustat, VAFSEO , chronic kidney disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 26, 2020 Category: Pharmaceuticals Source Type: news

Nursing home study suggests dialysis patients at greater risk of SARS-CoV-2 infection
(Johns Hopkins Medicine) It's widely known that the causative agent for COVID-19, the SARS-CoV-2 virus, can spread rapidly among residents in nursing homes and other long-term care facilities, leading to high numbers of cases and deaths in a very vulnerable population. According to a new study led by researchers at Johns Hopkins Medicine, residents receiving hemodialysis for chronic kidney disease may be at even greater risk for infection from the virus. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - August 25, 2020 Category: Infectious Diseases Source Type: news

Renalytix AI and AstraZeneca team up to improve chronic kidney disease outcomes
Artificial intelligence-enabled in vitro diagnostics company Renalytix AI announced today a research partnership with AstraZeneca to develop and launch medical strategies for cardiovascular, renal and metabolic diseases. (Source: mobihealthnews)
Source: mobihealthnews - August 21, 2020 Category: Information Technology Source Type: news

Racial/Ethnic Differences in Early Detection and Screening for Chronic Kidney Disease Among Adults in Hawaii: A 10-Year Population Health Study
(Source: CDC Preventing Chronic Disease)
Source: CDC Preventing Chronic Disease - August 20, 2020 Category: International Medicine & Public Health Tags: Public Health Source Type: news

CEUS helps predict chronic kidney disease progression
Clinicians may be able to use contrast-enhanced ultrasound (CEUS) features...Read more on AuntMinnie.comRelated Reading: Caution indicated with new GBCAs for kidney patients Prehydration not needed before contrast CT of kidneys Patients at risk for NSF might be safe with certain GBCAs Ultrasound predicts fistula success in dialysis patients Is ferumoxytol the alternative to gadolinium MRI agents? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 14, 2020 Category: Radiology Source Type: news

HCV Co-Infection and Treatment and CKD Risk in HIV HCV Co-Infection and Treatment and CKD Risk in HIV
Might HCV treatment have a role in mitigating the risk for developing chronic kidney disease among HIV/HCV co-infected individuals?AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 5, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

AstraZeneca Diabetes Drug Shows Promise in Severe Kidney Condition AstraZeneca Diabetes Drug Shows Promise in Severe Kidney Condition
Dapagliflozin has shown promise in a late-stage trial to help to slow chronic kidney disease, putting it on track for possible expanded approvals ahead of rival drugs.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 29, 2020 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Inflammatory Markers and Hospitalization With Infection in CKD Inflammatory Markers and Hospitalization With Infection in CKD
This study examined the association of blood levels of 4 inflammatory markers with infection risk in persons with chronic kidney disease.American Journal of Epidemiology (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 28, 2020 Category: Intensive Care Tags: Nephrology Journal Article Source Type: news

Research news tip sheet: Story ideas from Johns Hopkins Medicine
(Johns Hopkins Medicine) A new study looking at nearly three decades of data from some 54,000 people has determined that the overall prevalence of chronic kidney disease (CKD) for several racial/ethnic and socioeconomic groups in the United States has stabilized in recent years, except Mexican Americans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 23, 2020 Category: International Medicine & Public Health Source Type: news

Levels of Chronic Kidney Disease Stabilizing in the United States
TUESDAY, July 21, 2020 -- The prevalence of chronic kidney disease (CKD) in the United States has stabilized in recent years, according to a study published online July 16 in JAMA Network Open. Priya Vart, Ph.D., from the University of California in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 21, 2020 Category: Pharmaceuticals Source Type: news

Lymphoma Survivors at Risk for Developing Chronic Kidney Disease
Age, hypertension, hyperuricemia, and diabetes predict kidney disease in some lymphoma patients (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - July 20, 2020 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Nephrology, Oncology, Journal, Source Type: news

Lymphoma Survivors at Risk for Developing Chronic Kidney Disease
MONDAY, July 20, 2020 -- Lymphoma survivors are at substantial long-term risk for chronic kidney disease (CKD) development, according to a study published online July 11 in Leukemia& Lymphoma. Sanjal H. Desai, M.D., from the Medstar Washington... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 20, 2020 Category: Pharmaceuticals Source Type: news

Predicted Albumin-Creatinine Ratio Performs Well for CKD Screening, Staging, and Prognosis Predicted Albumin-Creatinine Ratio Performs Well for CKD Screening, Staging, and Prognosis
Researchers with the Chronic Kidney Disease Prognosis Consortium have developed equations to predict urine albumin-creatinine ratio from urine protein-creatinine ratio and dipstick protein.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 14, 2020 Category: Consumer Health News Tags: Nephrology News Source Type: news

Predicted Albumin-Creatinine Ratio Useful for CKD Screening
MONDAY, July 13, 2020 -- Predicted albumin-creatinine ratio (ACR) calculated from urine protein-creatinine ratio (PCR) or urine dipstick protein may be useful for chronic kidney disease (CKD) screening, staging, and prognosis, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 13, 2020 Category: Pharmaceuticals Source Type: news

09.07.20: Not intended for U.S. and UK Media
Bayer's finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetesFinerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care / Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events / Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized / Finerenone is the first investigational non-steroid...
Source: Bayer IR Newsfeed: Events - July 9, 2020 Category: Pharmaceuticals Source Type: news

Bayer ’ s finerenone meets primary endpoint in Phase III FIDELIO-DKD renal outcomes study in patients with chronic kidney disease and type 2 diabetes (for specialized target groups only)
Finerenone significantly reduced the combined primary endpoint of chronic kidney disease progression, kidney failure or kidney death versus placebo when added to standard of care / Finerenone significantly reduced the combined key secondary endpoint of cardiovascular death or non-fatal cardiovascular events / Chronic kidney disease impacts 4 in 10 patients with type 2 diabetes and is a deadly condition that is underrecognized / Finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to demonstrate renal and cardiovascular benefits in patients with chronic kidney disease and ty...
Source: Bayer Company News - July 9, 2020 Category: Pharmaceuticals Source Type: news

Some Kidney Disease-Related Terms Cause Patient Distress
WEDNESDAY, July 1, 2020 -- The obscurity and imprecision of terms related to chronic kidney disease (CKD) can be distressing for patients, according to a study published online June 25 in the Clinical Journal of the American Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 1, 2020 Category: Pharmaceuticals Source Type: news

Akebia Therapeutics Announces Approval of Vadadustat in Japan for the Treatment of Anemia Due to Chronic Kidney Disease in Dialysis-Dependent and Non-Dialysis Dependent Adult Patients
First Regulatory Approval for Akebia's HIF-PHI Marks Beginning of Next Phase of Akebia's Growth Story CAMBRIDGE, Mass., June 29, 2020 -- (Healthcare Sales & Marketing Network) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical compan... Biopharmaceuticals, Regulatory Akebia Therapeutics, vadadustat, chronic kidney disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 29, 2020 Category: Pharmaceuticals Source Type: news

Allopurinol Does Not Affect eGFR in Chronic Kidney Disease
THURSDAY, June 25, 2020 -- Allopurinol does not affect estimated glomerular filtration rate (eGFR) in patients with chronic kidney disease and does not result in a clinically meaningful benefit in kidney outcomes from serum urate reduction among... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 25, 2020 Category: Pharmaceuticals Source Type: news

Antioxidant agent may prevent chronic kidney disease and Parkinson's disease
(Osaka University) Researchers from Osaka University developed a novel dietary silicon-based antioxidant agent with renoprotective and neuroprotective effects. They showed in animals models of chronic kidney disease and Parkinson's disease that the intake of their agent protects the kidney and brain, respectively, from taking further damage. These findings could provide new insights into the treatment of patients with these diseases. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 18, 2020 Category: Biology Source Type: news

Researchers identify key steps in development of kidneys
(Massachusetts General Hospital) The discovery of how certain key structures in the kidneys are formed could have important implications for treating renal fibrosis (or scarring), a feature of chronic kidney disease (CKD). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 18, 2020 Category: International Medicine & Public Health Source Type: news

Blocking brain signals detected in the kidney could help unlock future treatments for kidney failure, heart disease, and stroke
Scientists have discovered an important cell signalling pathway in the kidney which if stopped, could hold the key to treating chronic kidney disease as well as other deadly conditions, including heart attack and stroke. (Source: University of Bristol news)
Source: University of Bristol news - June 15, 2020 Category: Universities & Medical Training Tags: Research, International, Health; Faculty of Health Sciences, Bristol Medical School, Faculty of Life Sciences, School of Biological Sciences, Faculty of Life Sciences, School of Cellular and Molecular Medicine; Press Release Source Type: news

Blood Pressure Targets in CKD: An Update on the Evidence Blood Pressure Targets in CKD: An Update on the Evidence
What are the optimal blood pressure targets in patients with chronic kidney disease? A new review looks at the evidence.Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 10, 2020 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Hemodynamic Effects of Propofol and Dexmedetomidine in Septic Patients Without Shock
Conclusions and Relevance: A minority of patients with sepsis who received either propofol or dexmedetomidine experienced an event. Patients with sepsis without shock receiving continuous infusions of propofol and dexmedetomidine experienced a negative hemodynamic event at similar frequencies, though the degree of hypotension seen with propofol was greater. The clinical significance of these adverse effects requires cautious use in sepsis and further investigation. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - June 4, 2020 Category: Consumer Health News Source Type: news

Type 2 Diabetes Update: Semaglutide and Linagliptin as Basal Insulin Alternatives
Cardiovascular comorbidities and risk reduction play a major new role in pharmacologic therapy for type 2 diabetes, with sodium-glucose transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists now recommended as part of the glucose-lowering regimen for patients who have established atherosclerotic cardiovascular disease (ASCVD) or indicators of high-risk, chronic kidney disease (CKD) or heart failure (HF). (Source: Caring for the Ages)
Source: Caring for the Ages - June 1, 2020 Category: Health Management Authors: Christine Kilgore Source Type: news

Environmental Chemical Exposure Tied to Kidney Disease in the U.S.
TUESDAY, May 26, 2020 -- Increased exposure to heavy metal lead, cadmium, or volatile organic compounds may be associated with an increased prevalence of chronic kidney disease (CKD), according to a study published online May 22 in the Clinical... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 26, 2020 Category: Pharmaceuticals Source Type: news

NICE publishes rapid COVID-19 guidelines on chronic kidney disease and interstitial lung disease
NICE has published two new rapid COVID-19 guidelines. (Source: NHS Networks)
Source: NHS Networks - May 19, 2020 Category: UK Health Source Type: news

COVID-19 rapid guideline: chronic kidney disease (CKD) [NG176], NICE
The guideline recommends that patients, including those who have symptoms of COVID-19, should be advised to continue taking their medicines (including ACE inhibitors, angiotensin receptor blockers, immunosuppressants and diuretics) as normal unless advised to stop by their healthcare professional. For patients who are stable on treatment, the guideline recommends they should be assessed to see whether it is safe to reduce the frequency of routine kidney function tests, taking into account any comorbidities and whether their CKD is progressive (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 18, 2020 Category: Consumer Health News Source Type: news

The Lancet Infectious Diseases: Sociodemographic factors associated with a positive test for COVID-19 in primary care
(The Lancet) Older age, being male, deprivation, living in a densely populated area, ethnicity, obesity, and chronic kidney disease are associated with a positive test for COVID-19, according to results from 3,802 people tested for SARS-CoV-2 (including 587 positive tests) in the UK. The observational study was conducted in between Jan 28 and April 4 using routine electronic health records data from GP practices across England (UK), and results are published in The Lancet Infectious Diseases journal. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 15, 2020 Category: International Medicine & Public Health Source Type: news

Too Many Sugary Sodas Might Harm Your Kidneys
THURSDAY, May 14, 2020 -- Drinking lots of sweetened soda may increase the risk of developing chronic kidney disease, two new studies find. " Consumption of 500 milliliters [16.9 fluid ounces] of a commercially available soft drink sweetened with... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 14, 2020 Category: General Medicine Source Type: news

States Vary in Vulnerability to COVID-19 Impact States Vary in Vulnerability to COVID-19 Impact
West Virginia's large elderly population and high rates of chronic kidney disease, cardiovascular disease, diabetes, and COPD make it the most vulnerable state to the coronavirus, according to a new analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 13, 2020 Category: Consumer Health News Tags: Infectious Diseases News Source Type: news

CKD, Heart Failure and Neprilysin Inhibition CKD, Heart Failure and Neprilysin Inhibition
Could treatment with neprilysin inhibitors effectively reduce the risk of heart failure in patients with chronic kidney disease?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2020 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Clinical- and surgery-specific risk factors for post-operative sepsis: a systematic review and meta-analysis of over 30 million patients
In conclusion, multiple-patient and surgery-related risk factors are associated with the development of post-operative sepsis. Recognizing these risk factors could assist in the pre-operative identification of patients at risk of post-operative sepsis. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 6, 2020 Category: Consumer Health News Source Type: news

Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Vadadustat achieved primary efficacy and cardiovascular safety endpoints Clear, consistent top-line data advances plan for vadadustat's New Drug Application and other global regulatory submissions Company to discuss top-line data on its scheduled fir... Biopharmaceuticals Akebia Therapeutics, vadadustat, chronic kidney disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 5, 2020 Category: Pharmaceuticals Source Type: news

All Your Coronavirus Questions, Answered
One of the worst symptoms of any plague is uncertainty—who it will strike, when it will end, why it began. Merely understanding a pandemic does not stop it, but an informed public can help curb its impact and slow its spread. It can also provide a certain ease of mind in a decidedly uneasy time. Here are some of the most frequently asked questions about the COVID-19 pandemic from TIME’s readers, along with the best and most current answers science can provide. A note about our sourcing: While there are many, many studies underway investigating COVID-19 and SARS-CoV-19, the novel coronavirus that causes the illn...
Source: TIME: Health - April 14, 2020 Category: Consumer Health News Authors: TIME Staff Tags: Uncategorized COVID-19 Explainer Source Type: news

Chronic Kidney Disease-Mineral and Bone Disorder Chronic Kidney Disease-Mineral and Bone Disorder
A new study provides important insights into changes in bone mineral parameters and the impacts on mortality in CKD-mineral bone disorder. What have we learned?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 14, 2020 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” sai...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Contrast-Induced Kidney Injury Risk Low in CKD Contrast-Induced Kidney Injury Risk Low in CKD
Contrast-induced kidney damage can occur after angiography in patients with chronic kidney disease, but the actual risk appears low and new data suggest it may be prevented by a novel drug.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 7, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early Diabetes Drug Slows Kidney Disease: DAPA-CKD Trial Stopped Early
AstraZeneca has announced that the phase 3 DAPA-CKD trial for dapagliflozin (Farxiga) in patients with chronic kidney disease has been halted early because of overwhelming efficacy.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Cardiorenal Protection in Advanced Chronic Kidney Disease Cardiorenal Protection in Advanced Chronic Kidney Disease
What have we learned about optimizing cardiorenal protection in advanced CKD from landmark papers published in 2018?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 31, 2020 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news